The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function

NCT05972564 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

74

Enrollment

OTHER

Sponsor class

Conditions

Obesity
Metabolic Syndrome

Interventions

DRUG: Empagliflozin 25 MG
DRUG: Placebo

Sponsor

Vanderbilt University Medical Center